Vertex Pharmaceuticals Heading $600? A Stock Outlook
Investors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
Looking to maximize your rewards? Discover the top credit cards with the best rewards programs tailored for your needs.
27,840 articlesInvestors keep asking if Vertex Pharmaceuticals is headed to $600. This article breaks down the core business, pipeli...
Nvidia still dominates AI hardware, but the stock's sparkle has cooled. This article breaks down the three big reason...
Chips led a broad market dip at midday as investors weighed AI headlines against inflation risks and possible rate hi...
Rocket Lab isn’t profitable yet, but the space company shows four clear catalysts for investors. Here are practical r...
Europe’s move toward UN-led tax dialogue signals a broader shift in global rules. This article breaks down what that ...
Berkshire Hathaway is changing under Greg Abel, shifting toward concentrated bets on Apple and Alphabet. This article...
Alphabet's Gemini delays raise questions about AI leadership and stock resilience. This guide analyzes what the lag m...
C3.AI reports two consecutive quarterly revenue declines, forcing investors to reassess its enterprise AI strategy as...
As self-driving tech moves from labs to city streets, control of the platform becomes the real battleground. This art...
Peloton reports fresh restructuring amid a stubborn demand slump and rising costs. The destruction peloton continues ...
Value stocks are regaining ground in May as investors rotate from growth; the VLUE, AVUV, and VBR trio are delivering...
A wave of AI compute demand is reshaping the chip landscape. While Cerebras eyes an IPO, the market shows that strong...